Intramuscular Ketamine for Suicidal Ideation

Summary

The objective of the present research protocol, a cross-over, subject-blinded, clinical trial, is to correlate changes in brain activity with reduction in suicidal ideation in response to a single intramuscular dose of ketamine. While ketamine is increasingly used as a rapid, antidepressant agent, there is accumulating evidence of additional anti-suicidal properties that may be distinct from its effects on depression. This pilot study will be used to determine (1) whether specific electroencephalogram (EEG) findings are correlated with response of SI to intramuscular (IM) ketamine, and (2) the effectiveness of IM ketamine in the treatment of acute SI.

Timeline

Start

2022-02

Primary completion

2022-03-24

Completion

2022-03-24

Outcome

Outcome not reported

Stopped: “PI leaving institution”

Drugs

Indications

No indication recorded.